Treatment Rates and Compliance to Treatment in Patients With Familial Hypercholesterolemia

Familial Hypercholesterolemia Clinical Trial

Official title:

Awareness, Treatment Rates and Compliance to Treatment in Patients With Serum LDL Cholesterol Higher Than 250 mg/dL, and Possible, Probable or Definite Familial Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04494464
• Other study ID #: Hypercholesterolemia
• Status: Completed
• Start date: January 2017
• Est. completion date: May 2017

Study information

• Verified date: July 2020
• Source: Ankara Yildirim Beyazit University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Familial hypercholesterolemia is a genetic disease characterized by increased levels of low density lipoprotein cholesterol (LDL-C). It is underdiagnosed and undertreated despite relatively high prevalence and significant association with increased mortality.

Description:

Patients older than 18 years old and have a serum low density LDL-C≥250 mg/dL were identified from the hospital database. A questionnaire was completed via phone. Patients were classified as definite, probable and possible familial hypercholesterolemia according to Dutch Lipid Clinical Network Criteria

Recruitment information / eligibility

• Status: Completed
• Enrollment: 367
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients older than 18 years old and have a serum LDL-C=250 mg/dL

Exclusion Criteria:

• Patients who refuse dto interview

• Serum TSH=10 mIU/mL

• Glomerulonephritis or nephrotic syndrome

• ALT or AST higher than 3 times of normal limits

• Serum triglyceride >400 mg/dL

Related Conditions & MeSH terms

• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II

Intervention

Other:
• No intervention

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ankara Yildirim Beyazit University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment rates	Patients with a serum LDL-C=250 mg/dL were identified from the database of our hospital. Dutch Lipid Clinical Network Criteria was used to classify patients as definite, probable and possible FH. Patients were reached by phone and a questionnaire was applied. The questionnaire consisted of questions related with clinical and physical examination findings defined in theDutch Lipid Clinical Network Criteria. Total cholesterol, LDL-C, HDL-C, triglyceride levels were obtained from the medical records. Patients were asked whether they were using lipid lowering drugs. If they were not using, the cause of this was asked. By this way, we determined the rate of use of lipid lowering drugs in patients with LDL-C=250 mg/dL and have definite, probable or possible familial hypercholesterolemia	January 2010 and December 2016